 |
|
|
|
|
|
|
|
 |
|
||||||
 |
 |
 |
 |
 |
 |
 |
|
Analyst Conference Summaries
Seagen
(formerly Seattle Genetics)
SGEN
conference date: February 15, 2023 @ 1:30 PM Pacific Time
Seagen Back on Track, Priced About Right [January 31, 2023]
Seagen With and Without a Merck Buyout [August 4, 2022]
Seagen Stock Is A Buy For Its Pipeline Value [September 15, 2021]
| 2022 | |||
| Seagen Q1 2022 |
Seagen Q2 2022 |
Seagen Q3 2022 |
Seagen Q4 2022 |
| April 28, 2022 | July 28, 2022 | Oct. 27, 2022 | Feb. 15, 2022 |
| 2021 | |||
| Seagen Q1 2021 |
Seagen
Q2 2021 |
Seagen
Q3 2021 |
Seagen
Q4 2021 |
| April 29, 2021 | July 29, 2021 | Oct. 28, 2021 | Feb. 9, 2022 |
| 2020 | |||
| Seagen
Genetics Q1 2020 |
Seattle Genetics Q2 2020 |
Seagen Q3 2020 |
Seagen Q4 2020 |
| April 30, 2020 | July 30, 2020 | Oct. 29, 2020 | Feb. 11, 2021 |
| 2019 | |||
| Seattle Genetics Q1 2019 |
Seattle Genetics Q2 2019 |
Seattle Genetics Q3 2019 |
Seattle Genetics Q4 2019 |
| April 25, 2019 | July 16, 2019 | Oct. 29, 2019 | Feb. 6, 2020 |
2018 |
|||
Not Available Q3 2018 |
|||
April 26, 2018 |
July 26, 2018 |
Oct. 25, 2018 |
Feb. 7, 2019 |
2017 |
|||
April 27, 2017 |
July 27, 2017 |
Oct. 26, 2017 |
Feb. 6, 2018 |
2016 |
|||
04/28/2016 |
07/26/2016 |
10/27/2016 |
02/09/2017 |
2015 |
|||
04/30/2015 |
07/30/2015 |
10/29/2015 |
02/09/2016 |
2014 |
|||
not available |
|||
07/31/2014 |
10/30/2014 |
02/10/2015 |
|
Seattle Genetics New Data Strengthens Buy Proposition [October 8, 2019]
Seattle Genetics Fairly Valued [May 14, 2018]
AML Therapies: Seattle Genetics vs. GlycoMimetics [July 15, 2016 at Seeking Alpha]
Seattle Genetics: The Long View [February 25, 2015 at SeekingAlpha]
Seattle Genetics develops antibody-based therapies for cancer. Adcetris is its first commercially approved therapy.
Seattle Genetics web site
Seattle Genetics investor relations page
More Analyst Conference Pages:
| AGEN |
| ALXN |
| AMAT |
| AMGN |
| APRE |
| ARWR |
| BIIB |
| BMY |
| CTDX |
| GILD |
| GLYC |
| ILMN |
| INCY |
| INO |
| IONS |
| ISRG |
| MCHP |
| MRNA |
| REGN |
| RNA |
| SANA |
| VRTX |
| VBLT |
| VRTX |
| VSTM |
Disclaimer: Our analyst summaries may include both our condensations of statements made by company representatives and our own analysis. They are not covered by any warranty. We cannot guarantee anything said by company representatives is true. We try not to make errors, but it is possible. These are my personal notes, not investment advise.
Copyright 2023 William P. Meyers